0001209191-18-001383.txt : 20180103 0001209191-18-001383.hdr.sgml : 20180103 20180103185902 ACCESSION NUMBER: 0001209191-18-001383 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171229 FILED AS OF DATE: 20180103 DATE AS OF CHANGE: 20180103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHAFER GREGORY W CENTRAL INDEX KEY: 0001193195 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 18507708 MAIL ADDRESS: STREET 1: C/O CERUS CORP STREET 2: 2411 STENWELL DRIVE CITY: CONCORD STATE: CA ZIP: 94520 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ADURO BIOTECH, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 BUSINESS PHONE: 510-848-4400 MAIL ADDRESS: STREET 1: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-12-29 0 0001435049 ADURO BIOTECH, INC. ADRO 0001193195 SCHAFER GREGORY W C/O ADURO BIOTECH, INC. 740 HEINZ AVENUE BERKELEY CA 94710 0 1 0 0 Chief Operating Officer Common Stock 2017-12-29 4 M 0 42000 0.82 A 190745 D Common Stock 2018-01-02 4 M 0 13068 0.82 A 203813 D Common Stock 2018-01-02 4 M 0 6932 1.45 A 210745 D Common Stock 2018-01-02 4 S 0 20000 7.6071 D 190745 D Stock Option (right to buy) 0.82 2017-12-29 4 M 0 42000 0.00 D 2023-11-26 Common Stock 42000 160390 D Stock Option (right to buy) 0.82 2018-01-02 4 M 0 13068 0.00 D 2023-11-26 Common Stock 13068 147322 D Stock Option (right to buy) 1.45 2018-01-02 4 M 0 6932 0.00 D 2025-01-09 Common Stock 6932 92813 D The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.45 to $7.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares subject to the Option became fully vested and exercisable as of July 1, 2017. The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015. /s/ Jennifer Lew, Attorney-in-Fact 2018-01-03